Common questions about Lidocain (FAQ)
Q: Is Lidocain the same thing as Novocain or marcaine?
A: Official sources classify Lidocaine as an amino amide local anesthetic. This is a chemical distinction that separates it from Novocain (Procaine), which is an ester-type anesthetic, and Marcaine (Bupivacaine), which is a different amide-type compound.
Q: Can children use Lidocain products, and is there a different dosage rule for them?
A: Official documentation advises that, when administering the drug, children should generally be given reduced dosages appropriate for their age and overall physical condition. This approach is generally used to accommodate potential differences in how children process the drug.
Q: Is Lidocain safe to use during pregnancy or while breastfeeding?
A: The drug is classified by regulatory authorities as Pregnancy Category B. This classification means that while animal studies have not shown harm to the fetus, controlled studies in pregnant women are lacking. Regulatory documents indicate that its use during pregnancy is considered appropriate only when the clinical need has been clearly established.
Q: Can applying heat or ice affect how Lidocain works on the skin?
A: Official product labeling includes restrictions against the application of external heat sources over a topical patch due to the risk of increased systemic absorption. Patient instructions for some formulations also advise against exposing the treated, numb area to hot or cold temperatures to prevent accidental injury.
Q: Can Lidocain be used on broken skin or open wounds?
A: Regulatory documents advise against applying certain topical formulations to skin that is cut, scratched, or significantly red. The presence of existing infections or open wounds in the application area is noted as a situation where use must proceed with caution.
Q: Does being older or having a lower body weight affect how Lidocain works?
A: Official labeling indicates that reduced dosages are generally necessary for older adults and acutely ill patients. This is due to the potential for reduced drug clearance, which can lead to higher systemic plasma concentrations and an increased risk of toxicity.
Q: How quickly does Lidocain start working when used for pain relief?
A: The time to onset varies by the form used. Following an intravenous bolus injection, the onset of action is described as rapid in official documents. For certain topical patches, the numbing effects are typically described as starting within 30 minutes of application.
Q: How long do the numbing effects of Lidocain usually last?
A: The duration of effect depends on the route of administration. For intravenous antiarrhythmic use, the effect following a single bolus is described in official documents as lasting approximately 15 to 20 minutes.
Q: Can Lidocain be used for long-term chronic pain, or just for short procedures?
A: Official documents describe certain topical formulations, such as the 5% patch, as approved by the FDA for the treatment of specific chronic conditions. Specifically, it is indicated for the management of pain associated with post-herpetic neuralgia (PHN), which is a long-term nerve pain condition.
Q: Why do doctors sometimes mix Lidocain with epinephrine (adrenaline)?
A: Lidocaine solutions used for injection are often combined with epinephrine (also known as adrenaline). This combination is used to prolong the duration of the numbing effect and to help reduce the rate of systemic absorption of Lidocaine from the site of injection.
Q: Can Lidocain cause a tingling or buzzing feeling before it goes numb?
A: Official documentation lists tingling or itching at the application site as a common side effect of topical use. In certain situations, tingling around the mouth (known as perioral paresthesia) is cited as an early sign that the drug's concentration in the bloodstream may be rising too high.
Q: What is the risk of having an allergic reaction to Lidocain?
A: The drug is contraindicated in anyone with a known history of hypersensitivity or allergy to Lidocaine or other similar amide-type anesthetics. While serious allergic reactions, like anaphylaxis, are cited in documentation, they are described as extremely rare events.
Q: Does using too much Lidocain at once increase the risk of side effects?
A: Regulatory documents indicate that the potential for adverse reactions is generally dose-dependent, meaning it correlates with the amount of drug that enters the bloodstream. Therefore, using excessive amounts increases the potential for higher systemic plasma concentrations and the related risk of toxicity.
Q: What are the signs that too much Lidocain has been absorbed into the body?
A: Early neurological signs associated with rising systemic concentrations may include dizziness, lightheadedness, nervousness, or tingling around the mouth. The more severe effects listed in official documents, which occur at very high concentrations, include convulsions/seizures, severe hypotension, and cardiac arrest.
Q: Does Lidocain show up on drug tests?
A: Scientific research has demonstrated that Lidocaine and its primary metabolite can be detected in plasma and urine following its administration. This detection is part of pharmacokinetic studies that examine how the body processes the drug.
Q: Are there certain skin conditions that make using Lidocain less appropriate?
A: Official documents note that the presence of existing skin infections or open wounds in the area of administration is a situation where caution is recommended.
Q: Is there any research on using Lidocain for chronic headaches or migraines?
A: Research has examined the use of Lidocaine for various types of chronic pain. While research has examined its use for chronic pain conditions, some specific applications, such as infusions for chronic headaches or migraines, are described in research documents as investigational.
Q: Can Lidocain affect my ability to drive or operate machinery?
A: Official patient information advises caution regarding driving or operating machinery. This is because the drug may cause effects such as drowsiness or dizziness, which have the potential to slow a person’s reflexes.
Q: Is it possible to become 'resistant' or tolerant to the effects of Lidocain over time?
A: Official prescribing information indicates that tolerance to elevated blood levels of the drug can develop. The degree of tolerance that may be observed is noted to vary depending on the patient’s overall physical status.
Q: Do official sources describe any specific instructions for removing Lidocain patches safely?
A: Official patient instructions advise specific steps for safe removal. These include avoiding contact with the sticky side, folding the used patch in half, placing it back in the original pouch, and washing hands immediately after handling.
Q: Are there any studies examining the use of Lidocain for pain after shingles (postherpetic neuralgia)?
A: Studies, including controlled trials, have examined the use of the 5% topical patch for pain relief. This research supported the FDA approval of this formulation specifically for use in treating pain associated with post-herpetic neuralgia (PHN), a complication of shingles.
Q: What is the risk of accidental exposure to pets or small children?
A: Official patient safety warnings strictly advise keeping the medication out of reach of children and pets. The warnings explicitly state that a new or used patch, if chewed or eaten, may cause harm to children or pets due to the concentrated drug content.
Q: Can Lidocain be used on sensitive areas like the face or mucous membranes?
A: Official formulations are available that are specifically indicated for use on certain sensitive areas, including the mucous membranes of the mouth and throat, to provide topical anesthesia.
Q: Is Lidocain a controlled substance or habit-forming?
A: Regulatory authorities do not classify Lidocaine as a controlled substance.
Q: Do official documents mention any potential interactions with alcohol?
A: Official patient information for Lidocaine injections includes warnings related to the use of alcohol during administration. This is because the combination may cause a drop in blood pressure, which can lead to feelings of dizziness and fainting.
Q: Are there reported cases of Lidocain-related systemic toxicity and what does that mean?
A: Systemic toxicity is a term used in regulatory documents to describe a rare but serious condition. It occurs when the concentration of the drug absorbed into the bloodstream is too high, potentially affecting the central nervous system (e.g., brain) and the cardiovascular system (e.g., heart).
Q: Can Lidocain be used before getting a vaccination or blood test?
A: Some topical formulations are indicated in official documents for use in providing local anesthesia prior to minor medical procedures. This includes numbing the skin before procedures such as venipuncture (blood tests).
Q: What does it mean if a product has Lidocain HCL versus just Lidocain?
A: Lidocaine HCl (hydrochloride) is a chemical salt form that is water-soluble and is often used in injectable solutions. Lidocaine (free base) is the non-ionized form, which is used in certain topical applications.
Q: Is it safe to exercise or sweat heavily while using a Lidocain patch?
A: Official administration instructions for certain patches advise avoiding activities like bathing or swimming due to the risk of poor adhesion or increased absorption. This suggests that activities causing heavy sweating may also be a limiting factor in patch use.
Q: Can Lidocain interfere with certain laboratory test results?
A: Official labeling for the drug may include information regarding interference with laboratory tests. It is generally noted that some metabolites of the drug may interfere with the results of certain diagnostic assays.
Q: What is the difference between a prescription Lidocain product and an over-the-counter one?
A: The difference is primarily based on concentration and regulatory classification. Prescription products are available in higher concentrations (e.g., 5%) for specific chronic conditions, while over-the-counter products are available in lower concentrations (e.g., 4%) for temporary minor pain relief.
